About this trial
CYCLE-CIPN is a proof-of-concept study designed to evaluate whether a prescribed aerobic exercise intervention has the potential to reduce the symptoms and functional impact of CIPN. The small number of participants in the proposed study will allow us to make decisions on the feasibility ("go/no-go") of a future larger-scale trial.
The protocol will assess feasibility and acceptability through recruitment, completion, adherence, program satisfaction, and safety. The study will also evaluate CIPN symptoms using both patient-reported and objective outcome measures, as well as fitness and quality of life outcomes. We aim to recruit 30 participants.
The Health Research Board of Alberta Cancer Committee has approved this study. Participants will participate in a stationary cycling-based aerobic exercise program biweekly for 12 weeks. Exercise sessions will be supervised and progressive, between 30 and 60 minutes each.
Eligibility criteria
Qualifiers
18 years or older
Cancer diagnosis stage I to III
CIPN: grade 1 (mild)
Receiving or have received chemotherapy treatment for cancer
Disqualifiers
Medical conditions that cause additional neuropathy symptoms (i.e. diabetes)
Any uncontrolled medical conditions
Will undergo surgery or radiation therapy during the study period
Are already receiving an aerobic exercise training program
Trial design
Treatments tested in this trial
- Exercise
Treatment groups
Sponsors and collaborators
University of Alberta
Lead sponsor
Cross Cancer Institute
Collaborator